ArticleNPJ science of food2026
The regulation mechanism of α-linolenic acid bioavailability by flaxseed lignan macromolecules in O/W emulsions.
Article in NPJ science of food, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Enhanced α-linolenic acid (ALA) intake effectively alleviates population sub-health status through dietary pattern modification, demonstrating substantial implications for promoting national health advancement. In this study, the multi-targeted regulation on ALA micellization, absorption, and lymphatic transport by natural flaxseed lignan macromolecules (FLM) and its thermal treatment products (FLM 150) was systematically investigated in an emulsion delivery system. In vitro Caco-2 transport assays revealed that ALA absorption was enhanced by 95% with the addition of FLM 150. Moreover, in vivo rat mesenteric lymph cannulation proved that FLM 150-enriched emulsion elevated ALA absorption by 493%, while significantly reducing lipid oxidation. Besides, lipidomic profiling indicated that FLM 150 enhanced triglyceride resynthesis during lipid resynthesis in intestinal epithelial cells, as well as promoted metabolism of ALA. Therefore, these findings established FLM 150 as a multi-target regulator optimizing ALA bioavailability through concurrent mucosal barrier reinforcement, oxidative stress mitigation, and lipid metabolic pathway redirection. These insights highlighted the potential of engineered emulsion systems to lipid absorption kinetics and intestinal metabolic outcomes, offering novel strategies for enhancing the bioavailability of ALA.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.